riluzole   Click here for help

GtoPdb Ligand ID: 2326

Synonyms: Rilutek® | RP-54274 | Tiglutik® (thickened oral suspension)
Approved drug PDB Ligand
riluzole is an approved drug (FDA (1995), EMA (1996))
Compound class: Synthetic organic
Comment: Marketed formulations may contain riluzole hydrochloride (PubChem CID 6419992).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 76.38
Molecular weight 234.01
XLogP 2.28
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Nc1nc2c(s1)cc(cc2)OC(F)(F)F
Isomeric SMILES Nc1nc2c(s1)cc(cc2)OC(F)(F)F
InChI InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
InChI Key FTALBRSUTCGOEG-UHFFFAOYSA-N
References
1. Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhie DJ, Yoon SH, Jo YH, Kim MS, Sung KW, Hahn SJ. (2006)
Interaction of riluzole with the closed inactivated state of Kv4.3 channels.
J Pharmacol Exp Ther, 319 (1): 323-31. [PMID:16815868]
2. Arun T, Tomassini V, Sbardella E, de Ruiter MB, Matthews L, Leite MI, Gelineau-Morel R, Cavey A, Vergo S, Craner M et al.. (2013)
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Brain, 136 (Pt 1): 106-15. [PMID:23365093]
3. Duprat F, Lesage F, Patel AJ, Fink M, Romey G, Lazdunski M. (2000)
The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.
Mol Pharmacol, 57 (5): 906-12. [PMID:10779373]
4. Grunnet M, Jespersen T, Angelo K, Frøkjaer-Jensen C, Klaerke DA, Olesen SP, Jensen BS. (2001)
Pharmacological modulation of SK3 channels.
Neuropharmacology, 40 (7): 879-87. [PMID:11378158]
5. Huang CS, Song JH, Nagata K, Yeh JZ, Narahashi T. (1997)
Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons.
J Pharmacol Exp Ther, 282 (3): 1280-90. [PMID:9316836]
6. Killestein J, Kalkers NF, Polman CH. (2005)
Glutamate inhibition in MS: the neuroprotective properties of riluzole.
J Neurol Sci, 233 (1-2): 113-5. [PMID:15949499]
7. Mostert J, Heersema T, Mahajan M, Van Der Grond J, Van Buchem MA, De Keyser J. (2013)
The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial.
ISRN Neurol, 2013: 370943. [PMID:23984093]
8. Mostert JP, Koch MW, Heerings M, Heersema DJ, De Keyser J. (2008)
Therapeutic potential of fluoxetine in neurological disorders.
CNS Neurosci Ther, 14 (2): 153-64. [PMID:18482027]
9. Richter JM, Schaefer M, Hill K. (2014)
Riluzole activates TRPC5 channels independently of PLC activity.
Br J Pharmacol, 171 (1): 158-70. [PMID:24117252]
10. Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Köhler R, Wulff H. (2009)
Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Mol Pharmacol, 75 (2): 281-95. [PMID:18955585]